Medication Monitor



Generic Name (Trade Name—Company)
Notes
May 1, 2011

Everolimus

(Afinitor—Novartis)
Treatment of pancreatic tumors

Uses:

Treatment of patients with progressive neuroendocrine tumors located in the pancreas that are unresctable, locally advanced, or metastatic

Approval was based on data from a randomized, double-blind, multicenter trial that compared use of everolimus 10 mg once daily plus best supportive care (n = 207) versus placebo plus best supportive care (n = 203) in patients with disease progression within the previous 12 months. Treatment with everolimus resulted in a statistically significant improvement in investigator-determined progression-free survival compared with placebo (median 11.0 vs. 4.6 mo).